Israel’s BiolineRX is to conduct Phase 1 clinical trials on sickle cell disease (SCD) patients at multiple locations in the US. It will use its motixafortide stem cell therapy (see here previously), currently used to treat multiple myeloma. SCD is caused by a mutation of the hemoglobin gene.
https://nocamels.com/2024/05/israeli-biopharma-firm-leading-us-trial-of-potential-scd-drug/